Source comparison
MOTS-C Legal Status: Research vs Consumer Comparison
In vitro research (cell culture, enzyme assays) Legal under FD&C Act Purchase order stating 'for research use only'; institutional affiliation optional but recommended 21 CFR Part 207 (research chemical) FDA-registered facilities only Fully compliant if source
This comparison does not assign a generated winner or score.
- In vitro research (cell culture, enzyme assays)
- Legal under FD&C Act
- Purchase order stating 'for research use only'; institutional affiliation optional but recommended
- 21 CFR Part 207 (research chemical)
- FDA-registered facilities only
- Fully compliant if sourced correctly and used in controlled lab settings
- In vivo animal research under IACUC protocol
- Legal with institutional oversight
- IACUC-approved protocol; institutional animal care facility registration
- 21 CFR Part 58 (Good Laboratory Practice for Nonclinical Studies)
- FDA-registered facilities with GLP compliance
- Legal but requires formal institutional approval and veterinary oversight
- Human clinical trials (investigational use)
- Legal only with IND approval
- FDA-approved Investigational New Drug (IND) application; IRB approval; informed consent protocols
- 21 CFR Part 312 (IND regulations)
- Must be supplied under clinical trial agreement with FDA-registered manufacturer
- Extremely rare for novel peptides; requires Phase 1 safety data submission
- Personal use (anti-aging, metabolic optimization)
- Illegal. Constitutes unapproved drug use
- Not applicable (prohibited)
- No legal pathway exists
- Not legally available through any channel
- This is the use case that generates most legal confusion. It's unambiguously prohibited
- Compounded formulation prescribed by physician
- Illegal under current FDA enforcement policy
- Not applicable (FDA issued warning letters to compounding pharmacies in 2023)
- Would require 503A or 503B compounding exemption, which FDA has denied for MOTS-C
- Not legally available
- FDA explicitly stated MOTS-C is not eligible for compounding exemptions as of 2023